市場調查報告書
商品編碼
1466640
抗菌藥物抗藥性監測市場:按組件、最終用戶分類 - 2024-2030 年全球預測Antimicrobial Resistance Surveillance Market by Component (Diagnostic Kits, Diagnostic Systems, Services), End-User (Hospitals, Research & Academic Institutes) - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年抗菌藥物抗藥性監測市場規模為56億美元,預計2024年將達59.6億美元,2030年將達到87.1億美元,複合年成長率為6.49%。
抗菌藥物抗藥性監測市場包括監測、分析和控制對抗生素、抗病毒藥物、抗真菌藥物和其他抗菌藥物產生抗藥性的微生物傳播的產品。抗菌藥物抗藥性監測的主要用途是提供有關各種環境中抗藥性病原體流行情況的資訊,例如醫院、社區健康中心、食品生產設施、畜牧業、水處理廠和環境樣本。世界各地的多重抗藥性細菌數量不斷增加,需要不斷監測,以確保現有治療方法得到適當調整。分子診斷技術的進步使得能夠及早檢測和鑑定抗生素抗藥性菌株。此外,醫療保健專業人員對抗生素管理計劃的認知不斷提高也鼓勵審慎處方。儘管存在成長前景,但一些挑戰阻礙了抗菌藥物抗藥性監測市場的進步。由於基礎設施和資金不足,低收入和中等收入國家的監測能力有限。世界各地採用的調查方法存在差異,阻礙了不同地區結果的可比較性。然而,就地檢驗設備的出現加快了診斷速度,並允許做出個人化的治療決策。基因組測序技術使我們能夠在人群層面上準確追蹤抗藥性機制和感染動態。除此之外,為了維持業務成長並為全球健康安全做出貢獻,相關人員正在尋求改進診斷工具以實現更快的檢測,探索非常規治療方法,並使用預測模型來維持業務成長並為全球健康安全做出貢獻。
主要市場統計 | |
---|---|
基準年[2023] | 56億美元 |
預測年份 [2024] | 59.6億美元 |
預測年份 [2030] | 87.1億美元 |
複合年成長率(%) | 6.49% |
以相對較低的成本快速檢測組件特異性電阻標記的套件發揮重要作用。
抗菌素抗藥性 (AMR) 監測市場由各種有助於識別和管理抗藥性病原體的組成部分組成。診斷套件對於準確、快速地檢測病原菌中的抗菌藥物抗藥性並及時採取適當的抗生素治療進行干預至關重要。這些套件採用多種技術來辨識微生物中的抗性基因,包括聚合酵素鏈鎖反應(PCR)、酵素結合免疫吸附檢測法(ELISA) 和次世代定序(NGS)。診斷系統包括基於實驗室的儀器,可促進 AMR 檢測的高通量篩檢和進階資料分析。 AMR 監測服務包括提供快速藥敏測試、全基因組定序和生物資訊分析的受託研究機構(CRO) 和實驗室。這些服務使醫療保健提供者能夠獲得尖端技術和專業知識來檢測抗藥性病原體,而無需投資昂貴的設備或專家。資料管理軟體在匯總、分析和解釋 AMR 監測過程中產生的大量資訊方面發揮關鍵作用。
最終用戶:醫院感染的增加增加了對下一代抗菌素抗藥性 (AMR) 監測的需求
醫院、研究和學術機構在對抗抗菌素抗藥性 (AMR) 的鬥爭中發揮著重要作用,並需要適合其需求的監測系統。醫院將優先考慮快速診斷解決方案,以指南臨床醫生提供適當的抗生素治療並防止抗藥性感染的傳播。研究和學術機構致力於闡明抗菌素抗藥性機制、開發新的治療方法以及促進醫療保健專業人員負責任地使用抗生素。
區域洞察
抗菌素抗藥性 (AMR) 正成為美洲和歐洲的主要公共衛生威脅。持續監測抗菌素抗藥性對於了解其對醫療保健系統日益成長的影響、指導政策決策以及實施有效策略以降低與抗藥性感染相關的風險至關重要。人類醫學、獸醫實踐、農業和食品生產領域抗生素的過度使用和濫用是美洲和歐洲抗菌素抗藥性水平上升的主要促進因素。在美洲和歐洲的已開發國家,抗生素製造商和供應商的行為受到嚴格的法律規範的約束。由於經濟快速成長、醫療保健支出增加以及有利的政府政策等因素,新興國家在應對抗菌素抗藥性方面潛力巨大。印度、中國和巴西等新興國家正大力投資抗生素抗藥性監測研究和開發,並促進官民合作關係關係來解決這個問題。各國政府正為研發 (R&D) 工作提供財政支持,以獎勵創新以解決抗菌素抗藥性問題。例如,2023年8月,英國政府投入2.1億英鎊的巨額投資,加強全球抗藥性細菌監測,這是抗菌素抗藥性(AMR)監測的關鍵方面。然而,加強監測系統、改善法律規範、投資研究和開發新治療方法對於有效應對此威脅至關重要。
FPNV定位矩陣
FPNV 定位矩陣對於評估抗菌藥物抗藥性監測市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對抗菌藥物抗藥性監測市場中供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4.競爭評估與資訊:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1. 抗菌藥物抗藥性監測市場的市場規模和預測是多少?
2.在抗菌素抗藥性監測市場的預測期內,有哪些產品、細分市場、應用和領域需要考慮投資?
3. 抗菌藥物抗藥性監測市場的技術趨勢和法規結構是什麼?
4.抗菌藥物抗藥性監測市場主要供應商的市場佔有率是多少?
5. 進入抗菌藥物抗藥性監測市場的適當型態和策略手段是什麼?
[196 Pages Report] The Antimicrobial Resistance Surveillance Market size was estimated at USD 5.60 billion in 2023 and expected to reach USD 5.96 billion in 2024, at a CAGR 6.49% to reach USD 8.71 billion by 2030.
The antimicrobial resistance surveillance market encompasses products to monitor, analyze, and control the spread of microorganisms that develop resistance to antibiotics, antivirals, antifungals, and other antimicrobial agents. The primary application of antimicrobial resistance surveillance is to provide information on the prevalence of resistant pathogens in various settings such as hospitals, community health centers, food production facilities, animal husbandry operations, water treatment plants, and environmental samples. The increasing prevalence of multidrug-resistant organisms worldwide necessitates constant monitoring to adapt existing treatments appropriately. Advances in molecular diagnostics techniques enable early detection and identification of antibiotic-resistant strains. Addtionally, growing awareness about antibiotic stewardship programs among healthcare professionals encourages prudent prescribing practices. Despite the growth prospects, several challenges hinder the antimicrobial resistance surveillance market progress. Inadequate infrastructure and funding in low and middle-income countries result in limited surveillance capabilities. Variability in laboratory methodologies employed worldwide hampers comparability of results across regions. However, the emergence of point-of-care testing devices expedites diagnosis and enables personalized treatment decisions. Harnessing genomic sequencing technologies allows for accurate tracking of resistance mechanisms and transmission dynamics at a population level. Along with these, to sustain business growth and contribute to global health security, stakeholders should focus on key areas like refining diagnostic tools for faster detection, exploring unconventional treatment approaches, utilizing artificial intelligence for predictive modeling.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 5.60 billion |
Estimated Year [2024] | USD 5.96 billion |
Forecast Year [2030] | USD 8.71 billion |
CAGR (%) | 6.49% |
Component: Significant role of diagnostic kits in offering rapid detection of specific resistance markers at relatively lower costs
The antimicrobial resistance (AMR) surveillance market comprises various components that help identify and manage drug-resistant pathogens. Diagnostic kits are essential for accurate and rapid detection of antimicrobial resistance in pathogens, enabling timely intervention with appropriate antibiotic therapy. These kits employ various techniques such as polymerase chain reaction (PCR), enzyme-linked immunosorbent assays (ELISA), and next-generation sequencing (NGS) to identify resistant genes in microorganisms. Diagnostic systems encompass laboratory-based instruments that facilitate high-throughput screening and advanced data analysis for AMR detection. AMR surveillance services include contract research organizations (CROs) and laboratories that provide accelerated susceptibility testing, whole-genome sequencing, and bioinformatics analysis. These services enable healthcare providers to access cutting-edge technology and expertise for detecting resistant pathogens without investing in expensive equipment or specialists. Data management software plays a crucial role in compiling, analyzing, and interpreting the vast amount of information generated during AMR surveillance.
End-User: Increasing incidence of hospital-acquired infections developed necessities for next generation antimicrobial resistance (AMR) surveillance
In the fight against antimicrobial resistance (AMR), hospitals and research & academic institutes play critical roles, necessitating tailored surveillance systems to address their distinct needs. Hospitals prioritize rapid diagnostic solutions that guide clinicians in providing appropriate antibiotic treatments and preventing the spread of resistant infections. Research & academic institutes focus on understanding antimicrobial resistance mechanisms, developing novel therapeutic approaches, and promoting responsible antibiotic use among healthcare professionals.
Regional Insights
Antimicrobial resistance (AMR) has emerged as a significant public health threat across the Americas and Europe. Continuous surveillance of AMR is crucial in understanding the growing impact on healthcare systems, guiding policy decisions, and implementing effective strategies to mitigate the risks associated with resistant infections. The major driving factors behind increased AMR levels in the Americas and Europe include the overuse and misuse of antimicrobials in human medicine, veterinary practice, agriculture, and food production sectors. In developed countries across the Americas and Europe, stringent regulatory frameworks govern the actions of manufacturers and providers of antimicrobial products. The potential associated with emerging countries in addressing AMR is immense due to factors such as rapid economic growth, increasing healthcare expenditure, and favorable government policies. Emerging economies like India, China, and Brazil are investing heavily in R&D for antimicrobial resistance surveillance and promoting public-private partnerships to address the issue. Governments provide financial support for research and development (R&D) efforts to incentivize innovation in addressing antimicrobial resistance. For instance, in August 2023, the UK government made a significant investment of £210 million to enhance global surveillance of drug-resistant bacteria, a critical aspect of Antimicrobial Resistance (AMR) surveillance. However, initiatives focusing on surveillance systems enhancement, regulatory oversight improvements, investment in research, and development of new treatments are crucial to combating this threat effectively.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Antimicrobial Resistance Surveillance Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antimicrobial Resistance Surveillance Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Antimicrobial Resistance Surveillance Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Accelerate Diagnostics, Inc., Becton, Dickinson and Company, bioMerieux SA, Cepheid, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Johnson & Johnson Services Inc., Liofilchem S.r.l., Lumed, Luminex Corporation, Merck & Co., Inc., Novo Holdings A/S, OpGen, Inc., Pfizer Inc., QIAGEN GmbH, Sanofi S.A., Thermo Fisher Scientific Inc., Venatorx Pharmaceuticals, Inc., Viatris Inc., Vivli Inc., and Wolters Kluwer N.V..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Antimicrobial Resistance Surveillance Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antimicrobial Resistance Surveillance Market?
3. What are the technology trends and regulatory frameworks in the Antimicrobial Resistance Surveillance Market?
4. What is the market share of the leading vendors in the Antimicrobial Resistance Surveillance Market?
5. Which modes and strategic moves are suitable for entering the Antimicrobial Resistance Surveillance Market?